• About Us
    • About EirGenix
    • Milestones
    • Vision and Mission
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
    • Videos
    • 360-Degree Virtual Tour
  • News
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP manufacturing–mammalian system
    • cGMP manufacturing–microbial system
    • Antibody-Drug Conjugate
  • Products
    • PRODUCT PIPELINE
    • CRM197 CARRIER PROTEIN
    • COVID-19 ANTIGEN RAPID TEST
  • Investor
    • Financials
      • Monthly Revenue
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
  • Contact Us
| English | 繁體中文
EN
  • EN
  • 繁中
  • LINKEDIN
  • YOUTUBE
  • Home
  • 首頁用資料
  • 區塊2
  • 12
首頁用資料
  • ABOUT US
    • Grow together
    • The primary task
    • Drug development
  • 區塊2
    • 2012
    • 12
    • 1000
  • 360-DEGREE VIRTUAL TOUR
  • Investor Relations
  • Careers

12

  • Sitemap
  • Privacy Policy
  • EIP
copyright © 2023 EirGenix, Inc. all rights reserved.
EirGenix, Inc.
  • Address No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180, Taiwan, R.O.C
  • TEL +886-2-7708-0123
  • FAX +886-2-7708-1666
  • E-mail service@eirgenix.com
  • LINKEDIN
  • YOUTUBE